Antigen self-presenting engineered migration body as well as preparation method and application thereof

Genetically engineered antigen autopresented engineered migration bodies from cell-derived antigens, combining MHC molecules, costimulator molecules and membrane-bound cytokines, directly presenting tumor antigen peptides, solving the manufacturing of engineered extracellular vesicles in tumor treatment The process difficulties and targeting enhancement have achieved efficient immune cell activation and tumor-specific killing.

CN119020292APending Publication Date: 2024-11-26TSINGHUA UNIVERSITY
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202310592904.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-24
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

Existing engineered extracellular vesicles have manufacturing process problems, half-life optimization and targeting improvement in tumor treatment, especially in achieving clinical-grade, large-scale manufacturing and tumor-specific targeting.

Method used

Using genetically engineered cell sources, retain their ability to activate and amplify immune cells, directly present tumor antigen polypeptides through antigen autopresentation engineered migrants, bind MHC molecules, costimulator molecules and membrane-bound cytokines to activate and Immune cells are amplified to mediate tumor-specific killing.

Benefits of technology

It achieves efficient activation and expansion of immune cells, enhances tumor-specific killing ability, improves the targeting and biocompatibility of treatment, reduces the immune response, and prolongs the in vivo half-life.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119020292A_ABST
    Figure CN119020292A_ABST
Patent Text Reader

Abstract

The invention provides an antigen self-presenting engineered migration body as well as a preparation method and application thereof. The antigen self-presenting engineered migration body is separated from source cells capable of activating and amplifying immune cells, retains the immune cell activating and amplifying functions of the source cells, and can mediate antigen-specific tumor killing.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biomedicine technology, and in particular to an antigen self-presenting engineered migrator and a preparation method and application thereof. Background Art

[0002] Extracellular vesicles (EVs) are nanoscale lipid bilayer vesicles secreted by cells for intercellular communication. EVs can contain transmembrane proteins, RNA, DNA, and cytoplasmic contents from the initiating cells. Drug delivery vehicles based on EVs have been used to treat diseases such as tumors.

[0003] The choice of cell type to produce EVs directly affects the properties and functions of EVs, because the derived EVs will retain many characteristics of the starting cells, including membrane rigidity, surface molecules, contents, etc. Using different cell types to obtain EVs will affect their anti-tumor effects. Currently, the source cell types of EVs include tumor cells, immune cells, and mesenchymal cells.

[0004] At present, tumor treatment based on extracellular vesicles can be divided into two categories: natural extracellular vesicles and engineered extracellular vesicles. Among them, the strategies of using engineered extracellular vesicles to treat tumors can be divided into the following categories:

[0005] First, EVs are used as drug delivery carriers to load tumor drugs and directly kill tumors. The types of loaded drugs include: 1) chemotherapy drugs, such as paclitaxel, doxorubicin, gemcitabine and cisplatin; 2) antisense oligonucleotides (ASO); 3) RNA drugs, such as siRNA, miRNA; 4) fusion vesicles formed by combining EVs and synthetic nanomaterials (see non-patent literature: The Role of Extracellular Vesicles in Cancer (Kalluri, Raghu, Kathleen M, Cell, 2023Apr 13; 186(8):1610-26)).

[0006] Second, EVs are used as drug delivery vehicles to load immunomodulatory molecules or antigens to regulate immune cell function, thereby indirectly killing tumors. For example, adding small molecule STING agonists to EVs can effectively activate antigen presenting cells and anti-tumor immunity, and adding RIG-I agonists can stimulate immune responses and inhibit tumor growth. Patent WO2011000551A1 discloses loading one or more cancer antigens into EVs by co-incubating cells with antigens or by directly loading after EV separation.

[0007] Tumor treatment technologies based on engineered extracellular vesicles are becoming increasingly important in the field of nanomedicine. Engineered extracellular vesicles have many advantages over synthetic nanoformulations: (1) high biocompatibility; (2) low immunogenicity, especially autologous EVs; (3) the ability to transport complex molecules and protect them from degradation; (4) potential active targeting capabilities; and (5) the ability to cross biological barriers. The disadvantages and difficulties of tumor treatment technologies based on engineered extracellular vesicles are: 1) how to achieve clinical-grade, large-scale manufacturing processes for engineered extracellular vesicles; 2) how to optimize the half-life of engineered extracellular vesicles; and 3) how to engineer extracellular vesicles to achieve tumor-specific targeting or immune cell-specific targeting.

[0008] Regarding prolonging the half-life: Patent CN115843241A discloses extracellular vesicles with improved half-life, which is achieved by modifying the surface of the extracellular vesicle with an albumin binding domain, specifically by forming a fusion protein with the albumin binding domain and the surface protein of the extracellular vesicle.

[0009] Regarding targeting: Patent CN111544391A discloses a method for preparing targeted extracellular vesicles for treating drug-resistant tumors. The preparation method mainly modifies the surface of DOX-loaded EVs with hyaluronic acid derivatives with targeted CD44. Summary of the invention

[0010] The present invention provides an engineered migrator that can directly present tumor antigen polypeptides, activate and amplify immune cells, and thus mediate tumor-specific killing. Different from the previous use of extracellular vesicles for drug delivery, the antigen self-presenting engineered migrator of the present application is derived from genetically engineered source cells with complete signals for activating and amplifying immune cells. It completely retains the characteristics of the source cells, allowing it to directly activate and amplify immune cells (such as T cells) and mediate antigen-specific tumor killing.

[0011] The first aspect of the present invention provides an antigen self-presenting engineered migrator.

[0012] The antigen self-presenting engineered migration body is an extracellular vesicle.

[0013] The antigen self-presenting engineered migration body is a nano-scale lipid bilayer vesicle.

[0014] The diameter of the antigen self-presenting engineered migrator is about 500nm-10μm, preferably 800nm-10μm, and further preferably 800nm-2μm; for example, 500nm, 600nm, 700nm, 800nm, 900nm, 1μm, 2μm, 3μm, 4μm, 5μm, 6μm, 7μm, 8μm, 9μm or 10μm, etc.

[0015] The antigen self-presenting engineered migration body has a marker molecule on its surface, such as a tetraspanin superfamily comprising four transmembrane domains, which may include 33 members, including Tspan1, Tspan2, Tspan3, Tspan4, Tspan5, Tspan6, Tspan7, Tspan8, Tspan9, Tspan10, Tspan11, Tspan12, Tspan13, Tspan14, Tspan15, Tspan16, Tspan17, Tspan18 , Tspan19, Tspan20 (UPK1B), Tspan21 (UPK1A), Tspan22 (PRPH2), Tspan23 (ROM1), Tspan24 (CD151), Tspan25 (CD53), Tspan26 (CD37), Tspan27 (CD82), Tspan28 (CD81), Tspan29 (CD9), Tspan30 (CD63), Tspan31, Tspan32 and Tspan33.

[0016] The antigen self-presenting engineered migrator contains a major histocompatibility complex (MHC) or a variant thereof that presents an antigen polypeptide. The MHC includes MHC class I molecules and / or MHC class II molecules. Preferably, the antigen self-presenting engineered migrator contains MHC class I molecules and MHC class II molecules that present an antigen polypeptide. Wherein, the MHC or a variant thereof that presents an antigen polypeptide is present on the surface and / or inside of the antigen self-presenting engineered migrator.

[0017] The antigens include endogenous or exogenous antigens.

[0018] The antigen self-presenting engineered migrator contains an antigen polypeptide.

[0019] The antigen or antigen polypeptide is present inside and / or on the surface of the antigen self-presenting engineered migrator.

[0020] The antigen polypeptide may be an antigen polypeptide presented by MHC class I molecules or an antigen polypeptide presented by MHC class II molecules, or may be a fusion protein of an antigen polypeptide presented by MHC class I molecules and an antigen polypeptide presented by MHC class II molecules.

[0021] Wherein, the fusion protein includes a signal peptide, an antigenic polypeptide, and a lysosomal localization protein (preferably LAMP1).

[0022] In a specific embodiment of the present invention, the fusion polypeptide comprises the amino acid sequence shown in SEQ ID NO:5.

[0023] Of course, in practical applications, the fusion protein can be a signal peptide, any one or more tumor antigen polypeptides, and a lysosomal localization protein.

[0024] The antigen polypeptide is derived from bacterial protein, fungal protein, viral protein, tumor antigen, tumor neoantigen or tumor cell antigen.

[0025] The antigen polypeptide is a peptide segment of bacterial protein, fungal protein, viral protein, tumor antigen, tumor neoantigen or tumor cell antigen decomposed by enzyme, which can be presented to the membrane surface by MHC.

[0026] The antigen self-presenting engineered migrator expresses a co-stimulatory molecule. Preferably, the co-stimulatory molecule is expressed on the membrane of the antigen self-presenting engineered migrator.

[0027] Preferably, the co-stimulatory molecules include one or more of CD28, CD80, CD86, CD40, ICAM1, ICAM2, LFA-3, HSA, VCAM-1, 4-1BB, 4-1BBL, CTLA-4, PD-1, ICOS or CD37L.

[0028] The antigen self-presenting engineered migrator expresses cytokines. Preferably, the cytokines include one or a combination of two or more of interleukins, colony stimulating factors, interferons, tumor necrosis factors, transforming growth factor-β, growth factors or chemokine families;

[0029] The interleukins include IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17, IL-18, IL-19, IL-20 , one or a combination of two or more of IL-21, IL-22, IL-23, IL-24, IL-25, IL-26, IL-27, IL-28, IL-29, IL-30, IL-31, IL-32, IL-33, IL-34, IL-35, IL-36, IL-37 or IL-38;

[0030] The colony stimulating factor includes one or a combination of two or more of G-CSF, M-CSF, GM-CSF, Multi-CSF, SCF or EPO;

[0031] The interferon includes IFN-α, IFN-β and / or IFN-γ;

[0032] The tumor necrosis factor includes TNF-α and / or TNF-β;

[0033] The transforming growth factor-β includes one or a combination of two or more of TGF-β1, TGF-β2, TGF-β3, TGFβ1β2 or BMP;

[0034] The growth factor comprises one or a combination of two or more of EGF, PDGF, FGF, HGF, IGF-1, IGF-II, LIF, NGF, OSM, PDECGF, TGF-α or VEGF;

[0035] The chemokine family includes one or a combination of two or more of the CXC / α subfamily, CC / β subfamily, C-type subfamily or CX3C subfamily; wherein the CXC / α subfamily includes one or a combination of two or more of IL-8, GRO / MGSA, PF-4, platelet basic protein, protein hydrolysis-derived product CTAP-Ⅲ and β-thromboglobulin, inflammatory protein 10 or ENA-78; the CC / β subfamily includes one or a combination of two or more of MIP-1α, MIP-1β, RANTES, monocyte chemoattractant protein-1, MCP-2, MCP-3 or I-309; the C-type subfamily includes lymphocyte chemoattractant protein; and the CX3C subfamily includes Fractalkine.

[0036] Preferably, the cytokine is a membrane-bound cytokine, such as one or a combination of two or more of membrane-bound IL-12, membrane-bound IL-15, membrane-bound IL10, membrane-bound IL18, membrane-bound IL2, membrane-bound IL7 or membrane-bound IL21.

[0037] Wherein, the membrane-bound cytokine is obtained by modifying the above-mentioned cytokine.

[0038] For example, membrane-bound IL-12 is formed by connecting the two subunits p35 and p40 of IL-12 to Fc6 and Fc9 respectively, and connecting to the transmembrane region of the B7 molecule to form a heterodimeric membrane protein. Alternatively, the two subunits p35 and p40 of IL12 are connected by a G4S linker and connected to the transmembrane region of the B7 molecule to form a homodimeric membrane protein.

[0039] Wherein, the amino acid sequence of Fc6 includes:

[0040] MWELEKDVYVVEVDWTPDAPGETVNLTCDTPEEDDITWTSDQRHGVIGSGKTLTITVKEFLDAGQYTCHKGGETLSHSHLLLHKKENGIWSTEILKNFKNKTFLKCEAPNYSGRFTCSWLVQRNMDLKFNIKSSSSSPDSRAVTCGMASLSAEKVTLDQRDYEKYSVSCQEDVTCPTAEETLPIELALEARQQNKYENYSTSFFIRDIIKPDPPKNLQMKPLKNSQVEVSWEYPDSWSTPHSYFSLKFFVRIQRKKEKMKETEEGCNQKGAFLVEKTSTEVQCKGGNVCVQAQDRYYNSSCSKWACVPCRVRS(SEQ ID NO:7);

[0041] The amino acid sequence of p35 includes:

[0042] DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVCTLPPSRDELTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFKLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK(SEQ ID NO:8);

[0043] The amino acid sequence of p40 includes:

[0044] DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPCRDELTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSALTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK(SEQ ID NO:9);

[0045] The amino acid sequence of Fc9 includes:

[0046] RVIPVSGPARCLSQSRNLLKTTDDMVKTAREKLKHYSCTAEDIDHEDITRDQTSTLKTCLPLELHKNESCLATRETSSTTRGSCLPPQKTSLMMTLCLGSIYEDLKMYQTEFQAINAALQNHNHQQIILDKGMLVAIDELMQSLNHNGETLRQKPPVGEADPYRVKMKLCILLHAFSTRVVTINRVMGYLSSA (SEQ ID NO: 10); the amino acid sequence of the transmembrane region of the B7 molecule includes:

[0047] TLVLFGAGFGAVITVVVIVVIIKCFCKHRSCFRRNEASRETNNSLTFGPE EALAEQTVFL (SEQ ID NO: 11).

[0048] The amino acid sequence of the G4S linker comprises GGGGSGGGGSGGGGS (SEQ ID NO: 12)

[0049] In a specific embodiment of the present invention, the membrane-bound IL-12 further comprises a signal peptide sequence, and the amino acid sequence of the signal peptide comprises:

[0050] MHHTSMGIKMESQIQVFVFVFLWLSGVDG (SEQ ID NO: 13)

[0051] In a specific embodiment of the present invention, the connection of the membrane-bound IL-12 homodimeric membrane protein includes the signal peptide-p35-G4S linker-p40-B7 molecular transmembrane region. It can also be a heterodimeric membrane protein containing two subunits, Fc6 and Fc9, and the connection is respectively:

[0052] Fc6 subunit: signal peptide-Fc6-G4S linker-p35-G4S linker-B7 transmembrane region;

[0053] Fc9 subunit: signal peptide-Fc9-G4S linker–p40-G4S linker-B7 molecule transmembrane region.

[0054] For example, membrane-bound IL-15 is a fusion membrane protein formed by connecting IL15 and IL15Rα with a G4S linker, which can act on IL15Rβγ on the T cell membrane.

[0055] The antigens include bacteria, fungi, viruses, tumor antigens, neo-tumor antigens or tumor cell antigens.

[0056] The bacteria include cocci, bacilli or spirochetes.

[0057] Preferably, the cocci are selected from Micrococcus ureabilis, Pneumococcus, Streptococcus lactis, Tetragenococcus, Urea Sporosarcina or Staphylococcus aureus.

[0058] Preferably, the bacillus is selected from Methanobacterium brevis, Bacillus subtilis, Fusobacterium, Bifidobacterium, Bacillus anthracis, Escherichia coli, Streptobacillus or Proteus.

[0059] Preferably, the spirochete is selected from Vibrio cholerae, Spirillum microspira or Treponema pallidum.

[0060] The fungus is selected from Streptomyces, Penicillium, Bacillus polymyxa, Geotrichum candidum, Aspergillus flavus or Candida.

[0061] The virus is selected from influenza virus, parainfluenza virus, herpes virus, measles virus, vesicular stomatitis virus, hepatitis B virus, hepatitis C virus, human immunodeficiency virus, lymphocytic choriomeningitis virus or human papillomavirus.

[0062] The tumor can be a hematological tumor or a solid tumor; preferably, the tumor is selected from prostate cancer, breast cancer, liver cancer, glioma, intestinal cancer, cervical cancer, non-small cell lung cancer, lung cancer, pancreatic cancer, gastric cancer, bladder cancer, skin cancer, rhabdomyosarcoma, tongue squamous cell carcinoma, nasopharyngeal carcinoma, ovarian cancer, placental choriocarcinoma, lymphoma, leukemia, rectal adenocarcinoma, medulloblastoma, meningioma, neurofibroma, ependymoma, schwannoma, astrocytoma, melanoma, mesothelioma, myeloma, chronic myeloid leukemia, acute myeloid leukemia, myelodysplastic syndrome, chronic lymphocytic leukemia, epidermoid carcinoma, colon cancer, thymic carcinoma, blood cancer, head and neck cancer or oropharyngeal cancer.

[0063] The antigen self-presenting engineered migrator can activate and / or expand immune cells.

[0064] Preferably, the antigen self-presenting engineered migrator presents the antigen polypeptide to immune cells, and cooperates with co-stimulatory molecules and cytokines to activate and / or amplify the immune cells.

[0065] The antigen self-presenting engineered migrator is separated from source cells or generated from tissues;

[0066] Preferably, the source cells may be in vitro cells.

[0067] Preferably, the source cells are living cells.

[0068] The source cells can activate and / or expand immune cells. Preferably, there are three signals for activating and / or expanding immune cells, the first signal is MHC or its variant, the second signal is a co-stimulatory molecule, and the third signal is a cytokine. Specifically, the source cells express MHC or its variant, co-stimulatory molecules and cytokines that present antigen polypeptides.

[0069] Preferably, the cytokine is a membrane-bound cytokine and is expressed on the membrane.

[0070] Of course, the source cell may be originally provided with the functions of the above three signals or with the functions of activating and / or amplifying immune cells, or may have partial functions or not have the functions of the above three signals. If it has partial functions or does not have the functions of the above three signals, it may be genetically modified to have the functions of the above three signals or to activate and / or amplify immune cells. For example, if the source cell is a tumor cell, it naturally carries the first signal, i.e., the function of the MHC class I molecule that naturally contains the antigen polypeptide, so the source cell that can separate the antigen self-presenting engineered migrator can be obtained by adding the second signal and the third signal to it through modification. For another example, if the source cell is an immune cell such as a dendritic cell, which naturally has MHC class I molecules and costimulatory signals, the antigen polypeptide part of the first signal and the third signal, i.e., cytokines, can be introduced thereto, and the source cell that can separate the antigen self-presenting engineered migrator can be obtained. For dendritic cells, in order to make it also present the antigen polypeptide of the MHC class II molecule, it is also possible to increase the expression of the MHC class II molecule by overexpressing CIITA. For dendritic cells, in order to increase the expression of their costimulatory molecules, cytokine stimulation can also be used.

[0071] The source cells can be genetically modified cells or naturally occurring cells.

[0072] The source cells may be human or non-human animal cells, preferably human tumor cells, human immune cells or human mesenchymal stem cells, and may be primary cells or cell lines, such as K562 cells.

[0073] The source cells may be cell lines, primary cells, cells with limited passage and / or organoids.

[0074] The non-human animal may be a non-human mammal, preferably, the non-human mammal may be a wild animal, a zoo animal, an economic animal, a pet, an experimental animal, etc. Preferably, the non-human mammal includes but is not limited to pigs, cattle, sheep, horses, donkeys, foxes, raccoon dogs, minks, camels, dogs, cats, rabbits, mice (such as rats, mice, guinea pigs, hamsters, gerbils, chinchillas, squirrels) or monkeys, etc.

[0075] The source cells include primary cells derived from the body or tumor cells with limited passage, tumor stromal cells, and / or tumor organoids.

[0076] The antigen or antigen polypeptide exists inside and / or on the surface of the source cell.

[0077] In a specific embodiment of the present invention, the source cells include but are not limited to immune cells, tumor cells, HEK293 cells (such as HEK293T cells), fibroblasts, amniotic cells, amniotic epithelial cells, placenta-derived cells, umbilical cord blood cells, endothelial cells, epithelial cells or mesenchymal stem cells.

[0078] The immune cells include lymphocytes (eg, T cells, B cells), dendritic cells, macrophages, granulocytes or mast cells.

[0079] The mesenchymal stem cells include but are not limited to bone marrow mesenchymal stem cells, urine mesenchymal stem cells, oral mesenchymal stem cells, adipose mesenchymal stem cells, placental mesenchymal stem cells, umbilical cord mesenchymal stem cells, periosteum mesenchymal stem cells or skin mesenchymal stem cells.

[0080] Among them, the antigen self-presenting engineered migration body can also be used as a delivery carrier or synergistically enhance the effect with the drug to be carried for disease treatment or prevention, such as delivery or combination with chemotherapeutic drugs, RNA drugs, antisense oligonucleotides, antibodies or immunomodulators.

[0081] In order to further increase the half-life of the antigen self-presenting engineered migrator in the body, anti-phagocytic proteins, such as one or more of CD47, CD24, MHC-I, PD-L1, STC-1 or GD2, are modified on its membrane.

[0082] In order to further increase the targeting of antigen self-presenting engineered migrator to organs, chemokine receptors, such as L-selectin and / or CCR7, are modified on its membrane. The organs are preferably spleen and / or lymph nodes.

[0083] The second aspect of the present invention provides a genetically modified cell, wherein the genetically modified cell contains an antigenic polypeptide, MHC or its variants expressing and presenting the antigenic polypeptide, a co-stimulatory molecule and a cytokine.

[0084] The genetically modified cells can produce the above-mentioned antigen self-presenting engineered migrator.

[0085] The cytokine is a membrane-bound cytokine and is expressed on the membrane.

[0086] The genetically modified cells can activate and / or expand immune cells.

[0087] The genetically modified cells include, but are not limited to, tumor cells, immune cells, HEK293 cells (eg, HEK293T cells), fibroblasts, amniotic cells, amniotic epithelial cells, placenta-derived cells, umbilical cord blood cells, endothelial cells, epithelial cells or mesenchymal stem cells.

[0088] The genetically modified cells may be human or non-human animal cells, preferably human tumor cells, human immune cells or human mesenchymal stem cells, and may be primary cells or cell lines, such as K562 cells.

[0089] The genetically modified cells may be cell lines, primary cells, cells with limited passage and / or organoids.

[0090] The non-human animal may be a non-human mammal, preferably, the non-human mammal may be a wild animal, a zoo animal, an economic animal, a pet, an experimental animal, etc. Preferably, the non-human mammal includes but is not limited to pigs, cattle, sheep, horses, donkeys, foxes, raccoon dogs, minks, camels, dogs, cats, rabbits, mice (such as rats, mice, guinea pigs, hamsters, gerbils, chinchillas, squirrels) or monkeys, etc.

[0091] The genetically modified cells include primary cells derived from the body or tumor cells with limited passage, tumor stromal cells, and / or tumor organoids.

[0092] The MHC or its variants, co-stimulatory molecules and cytokines included in the genetically modified cells may be partially contained in the cells themselves, partially genetically modified, or completely genetically modified. For example, if the cells themselves contain MHC, co-stimulatory molecules and cytokines are introduced through genetic modification; in addition, if only MHC class I molecules are contained, MHC class II molecules can be overexpressed through genetic engineering. If the cells themselves contain co-stimulatory molecules, MHC and cytokines are introduced through genetic modification; if the cells themselves contain cytokines, MHC or its variants and co-stimulatory molecules are introduced through genetic modification.

[0093] In a specific embodiment of the present invention, the cell is a tumor cell, which naturally carries the first signal, that is, it naturally contains MHC class I molecules that present antigen polypeptides, so the genetically modified cells that can separate antigen self-presenting engineered migration bodies can be obtained by adding the second signal and the third signal to it through modification. For another example, the cell is an immune cell such as a dendritic cell, which naturally has MHC class I molecules and costimulatory signals, and the antigen polypeptide part of the first signal and the third signal, i.e., cytokines, can be introduced thereto to obtain genetically modified cells that can separate antigen self-presenting engineered migration bodies. For dendritic cells, in order to enable them to present antigen polypeptides of MHC class II molecules, the expression of MHC class II molecules can also be increased by overexpressing CIITA. For dendritic cells, in order to increase the expression of their costimulatory molecules, cytokine stimulation can also be used.

[0094] The antigen polypeptide is derived from bacterial protein, fungal protein, viral protein, tumor antigen, tumor neoantigen or tumor cell antigen.

[0095] The antigen polypeptide is a peptide segment of bacterial protein, fungal protein, viral protein, tumor antigen, tumor neoantigen or tumor cell antigen decomposed by enzymes, which can be presented to the membrane surface by MHC or its variants.

[0096] The antigen or antigen polypeptide exists inside and / or on the surface of the genetically modified cell.

[0097] The third aspect of the present invention provides a method for preparing the above-mentioned genetically modified cells, which comprises introducing a nucleic acid sequence encoding a membrane-bound cytokine into the genetically modified cells.

[0098] The preparation method comprises introducing nucleic acid encoding antigen polypeptide and / or co-stimulatory molecule into genetically modified cells.

[0099] The MHC includes MHC class I molecules and / or MHC class II molecules. Preferably, the genetically modified cells include connecting the antigen polypeptide presented by the MHC class I molecule and the antigen polypeptide presented by the MHC class II molecule into a fusion protein.

[0100] The preparation method comprises introducing nucleic acid encoding fusion protein into gene-modified cells.

[0101] The preparation method comprises stimulating genetically modified cells with cytokines to increase the expression amount of costimulatory molecules.

[0102] The genetically modified cells include tumor cells, immune cells, HEK293 cells (eg, HEK293T cells), fibroblasts, amniotic cells, amniotic epithelial cells, placenta-derived cells, umbilical cord blood cells, endothelial cells, epithelial cells or mesenchymal stem cells.

[0103] The fourth aspect of the present invention provides a genetically modified dendritic cell, wherein the genetically modified dendritic cell contains an antigenic polypeptide, expresses MHC class I molecules and / or MHC class II molecules, and a membrane-bound cytokine.

[0104] The genetically modified dendritic cells also express co-stimulatory molecules, and the expression of co-stimulatory molecules is preferably further stimulated by cytokines.

[0105] A fifth aspect of the present invention provides a method for constructing genetically modified dendritic cells, the method comprising:

[0106] A) introducing a nucleic acid encoding a fusion protein consisting of an antigen polypeptide presented by an MHC class I molecule and an antigen polypeptide presented by an MHC class II molecule into a dendritic cell; preferably, the method further comprises causing the dendritic cell to overexpress CIITA;

[0107] B) introducing nucleic acid encoding a co-stimulatory molecule into dendritic cells;

[0108] C) Introducing a nucleic acid encoding a membrane-bound cytokine into dendritic cells.

[0109] The introduction includes viral transfection.

[0110] The sixth aspect of the present invention provides a genetically modified tumor cell, wherein the genetically modified tumor cell contains an antigenic polypeptide, expresses MHC class I molecules and / or MHC class II molecules and co-stimulatory molecules.

[0111] The seventh aspect of the present invention provides a method for constructing a genetically modified tumor cell, the method comprising:

[0112] A) introducing a nucleic acid encoding a fusion protein consisting of an antigen polypeptide presented by an MHC class I molecule and an antigen polypeptide presented by an MHC class II molecule into tumor cells;

[0113] B) introducing nucleic acid encoding a co-stimulatory molecule into dendritic cells;

[0114] The introduction includes viral transfection.

[0115] The eighth aspect of the present invention provides a method for preparing an antigen self-presenting engineered migrator, wherein the antigen self-presenting engineered migrator is separated from the above-mentioned genetically modified cells or the genetically modified cells obtained by the above-mentioned preparation method.

[0116] Preferably, the genetically modified cells or the source cells are caused to move relative to each other to generate migratory bodies derived from the cells. Further preferably, the method further comprises isolating migratory bodies generated by the cells.

[0117] The preparation method comprises subjecting the genetically modified cells or the above-mentioned source cells to low osmotic pressure treatment, for example, placing the genetically modified cells or the source cells in a low osmotic buffer solution.

[0118] Preferably, the method for isolating antigen self-presenting engineered migrator from genetically modified cells comprises cytokine stimulation and induction. The cytokine may be IFNγ, preferably at a concentration of 10-30 ng / ml. The induction comprises the addition of Latrunculin A, Latrunculin B, cytochalasin A, cytochalasin B, cytochalasin C, cytochalasin D and / or cytochalasin E. Preferably, the induction may be K-DPBS with the addition of latrunculin A.

[0119] In a specific embodiment of the present invention, the preparation method comprises:

[0120] The genetically modified cells were cultured in medium containing IFNγ;

[0121] Then, the genetically modified cells are incubated in a culture medium containing K-DPBS containing latrunculin A; preferably, the incubation is carried out in a shaker at a rotation speed of 30-50 rpm.

[0122] The antigen self-presenting engineered migratoria were then isolated and obtained.

[0123] Preferably, the separation includes discarding the supernatant, washing with h-KDPBS (75% KDPBS), and then centrifuging after adding h-KDPBS-BSA. Wherein, the centrifugation is preferably differential centrifugation, that is, centrifugation at a low speed first, and then centrifugation at a gradually increasing speed. In a specific embodiment of the present invention, the centrifugation includes centrifugation at 200-400x g for 5-20min, taking the supernatant, and then centrifuging at 400-600x g for 5-20min, taking the supernatant, and then centrifuging at 10000-30000x g for 40-80min after filtration, discarding the supernatant (centrifugation at 10000-30000x g for 40-80min, discarding the supernatant can be repeated 1-5 times), and the precipitate is the antigen self-presenting engineered migration body. Wherein, the filtration can use a filter or an extruder, preferably with a pore size of about 30nm to about 10000nm.

[0124] The antigen self-presenting engineered migration body membrane is enriched with integrins or their functional fragments.

[0125] The method may be in vivo or in vitro or ex vivo.

[0126] The ninth aspect of the present invention provides an application of the above-mentioned antigen self-presenting engineered mobile body, the above-mentioned genetically modified cell, the genetically modified cell obtained by the above-mentioned preparation method, or the antigen self-presenting engineered mobile body obtained by the above-mentioned preparation method in activating and / or amplifying immune cells or preparing products for treating or preventing diseases.

[0127] The disease is an infectious disease, an autoimmune disease or a tumor.

[0128] The infectious diseases include bacterial infection, viral infection or fungal infection.

[0129] The bacteria include cocci, bacilli or spirochetes.

[0130] Preferably, the cocci are selected from Micrococcus ureabilis, Pneumococcus, Streptococcus lactis, Tetragenococcus, Urea Sporosarcina or Staphylococcus aureus.

[0131] Preferably, the bacillus is selected from Methanobacterium brevis, Bacillus subtilis, Fusobacterium, Bifidobacterium, Bacillus anthracis, Escherichia coli, Streptobacillus or Proteus.

[0132] Preferably, the spirochete is selected from Vibrio cholerae, Spirillum microspira or Treponema pallidum.

[0133] The fungus is selected from Streptomyces, Penicillium, Bacillus polymyxa, Geotrichum candidum, Aspergillus flavus or Candida.

[0134] The virus is selected from influenza virus, parainfluenza virus, herpes virus, measles virus, vesicular stomatitis virus, hepatitis B virus, hepatitis C virus, human immunodeficiency virus, lymphocytic choriomeningitis virus or human papillomavirus.

[0135] The tumor can be a hematological tumor or a solid tumor; preferably, the tumor includes prostate cancer, breast cancer, liver cancer, glioma, intestinal cancer, cervical cancer, non-small cell lung cancer, lung cancer, pancreatic cancer, gastric cancer, bladder cancer, skin cancer, rhabdomyosarcoma, tongue squamous cell carcinoma, nasopharyngeal carcinoma, ovarian cancer, placental choriocarcinoma, lymphoma, leukemia, rectal adenocarcinoma, medulloblastoma, meningioma, neurofibroma, ependymoma, schwannoma, astrocytoma, melanoma, mesothelioma, myeloma, chronic myeloid leukemia, acute myeloid leukemia, myelodysplastic syndrome, chronic lymphocytic leukemia, epidermoid carcinoma, colon cancer, thymic carcinoma, blood cancer, head and neck cancer or oropharyngeal cancer.

[0136] The tenth aspect of the present invention provides the use of the above-mentioned antigen self-presenting engineered mobile body, the above-mentioned genetically modified cell, the genetically modified cell obtained by the above-mentioned preparation method, or the antigen self-presenting engineered mobile body obtained by the above-mentioned preparation method in combination with chemotherapeutic drugs and / or immunomodulators in activating and / or amplifying immune cells or preparing products for treating or preventing diseases.

[0137] Preferably, the chemotherapeutic drug is selected from alkylating agents, antimetabolites, plant anticancer drugs, hormones, antibiotics or immune preparations. Further preferably, the chemotherapeutic drug is selected from paclitaxel, doxorubicin, gemcitabine or cisplatin.

[0138] Preferably, the immunomodulator includes but is not limited to immune checkpoint inhibitors, such as one or more of PD-1 antibody, PD-L1 antibody, CTLA-4 antibody, Tim-3 antibody, LAG-3 antibody or TIGHT antibody.

[0139] The combination of antigen self-presenting engineered migsomes and immune checkpoint inhibitors can achieve a synergistic effect, that is, antigen self-presenting engineered migsomes kill tumors by activating and amplifying T cells, but cannot avoid T cell exhaustion caused by PD-1 on T cells. Therefore, immune checkpoint inhibitors can block signals that inhibit T cells, inhibit T cell apoptosis and exhaustion, and further enhance the activation and amplification of T cells by antigen self-presenting engineered migsomes.

[0140] The disease is an infectious disease, an autoimmune disease or a tumor.

[0141] The infectious diseases include bacterial infection, viral infection or fungal infection.

[0142] The bacteria include cocci, bacilli or spirochetes.

[0143] Preferably, the cocci are selected from Micrococcus ureabilis, Pneumococcus, Streptococcus lactis, Tetragenococcus, Urea Sporosarcina or Staphylococcus aureus.

[0144] Preferably, the bacillus is selected from Methanobacterium brevis, Bacillus subtilis, Fusobacterium, Bifidobacterium, Bacillus anthracis, Escherichia coli, Streptobacillus or Proteus.

[0145] Preferably, the spirochete is selected from Vibrio cholerae, Spirillum microspira or Treponema pallidum.

[0146] The fungus is selected from Streptomyces, Penicillium, Bacillus polymyxa, Geotrichum candidum, Aspergillus flavus or Candida.

[0147] The virus is selected from influenza virus, parainfluenza virus, herpes virus, measles virus, vesicular stomatitis virus, hepatitis B virus, hepatitis C virus, human immunodeficiency virus, lymphocytic choriomeningitis virus or human papillomavirus.

[0148] The tumor can be a hematological tumor or a solid tumor; preferably, the tumor includes prostate cancer, breast cancer, liver cancer, glioma, intestinal cancer, cervical cancer, non-small cell lung cancer, lung cancer, pancreatic cancer, gastric cancer, bladder cancer, skin cancer, rhabdomyosarcoma, tongue squamous cell carcinoma, nasopharyngeal carcinoma, ovarian cancer, placental choriocarcinoma, lymphoma, leukemia, rectal adenocarcinoma, medulloblastoma, meningioma, neurofibroma, ependymoma, schwannoma, astrocytoma, melanoma, mesothelioma, myeloma, chronic myeloid leukemia, acute myeloid leukemia, myelodysplastic syndrome, chronic lymphocytic leukemia, epidermoid carcinoma, colon cancer, thymic carcinoma, blood cancer, head and neck cancer or oropharyngeal cancer.

[0149] The eleventh aspect of the present invention provides a medicine or a pharmaceutical composition, which comprises the above-mentioned antigen self-presenting engineered migration body, the above-mentioned genetically modified cells or the genetically modified cells obtained by the above-mentioned preparation method, and pharmaceutically acceptable excipients.

[0150] The pharmaceutical composition also includes components used in combination with the above-mentioned antigen self-presenting engineered migrator, the above-mentioned genetically modified cells or the genetically modified cells obtained by the above-mentioned preparation method.

[0151] The components can be any components that can treat the same disease or reduce side effects, etc. For example, the components are selected from chemotherapeutic drugs, RNA drugs, antisense oligonucleotides, antibodies or immunomodulators.

[0152] The chemotherapeutic drug is selected from alkylating agents, antimetabolites, plant anticancer drugs, hormones, antibiotics, and immune preparations, preferably paclitaxel, doxorubicin, gemcitabine, or cisplatin.

[0153] The RNA drug is selected from siRNA and / or miRNA.

[0154] The immunomodulators include but are not limited to immune checkpoint inhibitors, such as one or more of PD-1 antibodies, PD-L1 antibodies, CTLA-4 antibodies, Tim-3 antibodies, LAG-3 antibodies or TIGHT antibodies.

[0155] The drug or pharmaceutical composition can be administered by any suitable route, such as gastrointestinal administration (e.g., oral administration) or parenteral administration (e.g., intravenous, intramuscular, subcutaneous, intradermal, intraorgan, intranasal, intraocular, instillation, intracerebral, intrathecal, transdermal or rectal administration, etc.).

[0156] The drug or pharmaceutical composition can be in any suitable dosage form, such as a dosage form for gastrointestinal administration or a dosage form for parenteral administration, preferably including but not limited to tablets, pills, powders, granules, capsules, lozenges, syrups, liquids, emulsions, microemulsions, suspensions, injections, sprays, aerosols, powder sprays, lotions, ointments, plasters, pastes, patches, eye drops, nasal drops, sublingual tablets, suppositories, aerosols, effervescent tablets, pills or gels, etc.

[0157] Various dosage forms of the drug or pharmaceutical composition can be prepared according to conventional production methods in the pharmaceutical field.

[0158] The drug or pharmaceutical composition may contain 0.01-99.5% (specifically, 0.01%, 0.1%, 0.5%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 99% or 99.5%) of the antigen self-presenting engineered migration body or the genetically modified cell.

[0159] The medicine or pharmaceutical composition is for human or veterinary use.

[0160] The twelfth aspect of the present invention provides a method for activating and / or amplifying immune cells, the method comprising contacting the above-mentioned antigen self-presenting engineered migration body, the above-mentioned genetically modified cells, the genetically modified cells obtained by the above-mentioned preparation method, the antigen self-presenting engineered migration body obtained by the above-mentioned preparation method, or the above-mentioned drug or drug composition with immune cells.

[0161] The method comprises activating and expanding immune cells in vivo and / or in vitro.

[0162] Preferably, the method comprises applying an effective amount of the above-mentioned antigen self-presenting engineered migrator, the above-mentioned genetically modified cell, the genetically modified cell obtained by the above-mentioned preparation method, or the above-mentioned drug or pharmaceutical composition to an individual in need.

[0163] The thirteenth aspect of the present invention provides a method for treating or preventing a disease, the method comprising contacting the above-mentioned antigen self-presenting engineered migration body, the above-mentioned genetically modified cell, the genetically modified cell obtained by the above-mentioned preparation method, or the above-mentioned drug or drug composition with immune cells.

[0164] Preferably, the method comprises applying an effective amount of the above-mentioned antigen self-presenting engineered migrator, the above-mentioned genetically modified cell, the genetically modified cell obtained by the above-mentioned preparation method, or the above-mentioned drug or pharmaceutical composition to an individual in need.

[0165] The disease is an infectious disease, an autoimmune disease or a tumor;

[0166] The infectious diseases include bacterial infection, viral infection or fungal infection.

[0167] The "antigen self-presentation xx" mentioned in the present invention means that xx itself has the ability to present antigens, wherein the antigen presentation can be in the form of presenting polypeptide molecules after the antigen is hydrolyzed.

[0168] The "co-stimulatory molecules" described in the present invention are molecules involved in the transmission of co-stimulatory signals, and are cell surface molecules and their ligands that provide co-stimulatory signals for the complete activation of immune cells. Different cells express different co-stimulatory molecules on their surfaces, for example, T cells express CD28 while antigen presenting cells (APCs) express B7-1 (CD80) and B7-2 (CD86).

[0169] The "cytokines" described in the present invention are small molecule proteins with a wide range of biological activities that are synthesized and secreted by cells (immune cells or non-immune cells) upon stimulation. Cytokines generally regulate cell growth, differentiation and effects and control immune responses by binding to corresponding receptors.

[0170] The "tumor antigen" mentioned in the present invention generally refers to the antigenic substances that appear or are overexpressed during the occurrence and development of tumors. It includes tumor-specific antigens (TSA) and tumor-associated antigens (TAA). TSA is an antigen that exists on tumor tissues but not on normal tissues; TAA is an antigen that is held by non-tumor cells and also exists on normal cells, and only changes in quantity are shown in tumor tissues.

[0171] The "neo-tumor antigens" mentioned in the present invention refer to gene-mutated antigens presented on the surface of tumor cells. They are true exogenous proteins and are not expressed in normal cells.

[0172] The "tumor cell antigen" of the present invention generally refers to any substance in a tumor cell that can induce an immune response. This definition includes, but is not limited to, complete tumor cells containing all relevant antigens as antigens, as well as any components of the cell, such as proteins in the plasma membrane, cell surface or membrane, or unique carbohydrate motifs associated with the cell surface. This definition also includes those antigens from cells that require special treatment of the cells to obtain.

[0173] The term "pharmaceutically acceptable" as used herein refers to a substance that neither significantly irritates an organism nor inhibits the biological activity and properties of the active substance of the administered product.

[0174] The "pharmaceutically acceptable excipients" mentioned in the present invention include, but are not limited to, one or more of carriers, excipients, diluents, wetting agents, fillers, binders, lubricants, disintegrants, antioxidants, buffers, suspending agents, solubilizers, thickeners, stabilizers, flavoring agents or preservatives.

[0175] As used herein, "treating" means slowing, interrupting, preventing, controlling, stopping, alleviating, or reversing the progression or severity of a sign, symptom, disorder, condition, or disease after the disease has begun to develop, but does not necessarily involve the complete elimination of all disease-related signs, symptoms, conditions, or disorders.

[0176] The "effective amount" of the present invention refers to the amount or dosage of the drug or pharmaceutical composition of the present invention that provides the desired treatment or prevention after being administered to an individual or an organ in a single or multiple doses.

[0177] The term "prevention" as used herein refers to a method implemented to prevent or delay the occurrence of a disease, disorder or symptom in an organism.

[0178] The "individual" described in the present invention can be a human or a non-human mammal, and the non-human mammal can be a wild animal, a zoo animal, an economic animal, a pet, an experimental animal, etc. Preferably, the non-human mammal includes but is not limited to pigs, cattle, sheep, horses, donkeys, foxes, raccoon dogs, minks, camels, dogs, cats, rabbits, mice (such as rats, mice, guinea pigs, hamsters, gerbils, chinchillas, squirrels) or monkeys, etc.

[0179] The "tumor" of the present invention can be any undesirable cell proliferation (or any disease that manifests itself as undesirable cell proliferation), neoplasm, or increased tendency or risk of undesirable cell proliferation, neoplasm or tumor. It can be benign or malignant, and can be primary or secondary (metastatic). Neoplasm can be any abnormal growth or proliferation of cells and can be located in any tissue. Examples of tissues include adrenal gland, adrenal medulla, anus, appendix, bladder, blood, bone, bone marrow, brain, breast, cecum, central nervous system (including or excluding the cerebrum), cerebellum, cervix, colon, duodenum, endometrium, epithelial cells (e.g., renal epithelial cells), gallbladder, esophagus, glial cells, heart, ileum, jejunum, kidney, lacrimal gland, larynx, liver, lung, lymph, lymph node, lymphoblastic cells, maxilla, mediastinum, mesentery, myometrium, nasopharynx, omentum, oral cavity, ovary, pancreas, parotid gland, peripheral nervous system, peritoneum, pleura, prostate, salivary gland, sigmoid colon, skin, small intestine, soft tissue, spleen, stomach, testis, thymus, thyroid, tongue, tonsils, trachea, uterus, vulva, leukocytes. Further preferably, the tumor is selected from prostate cancer, breast cancer, liver cancer, glioma (e.g., glioma), intestinal cancer, cervical cancer, non-small cell lung cancer, lung cancer, pancreatic cancer, gastric cancer, bladder cancer, skin cancer, rhabdomyosarcoma, tongue squamous cell carcinoma, nasopharyngeal carcinoma, ovarian cancer, placental choriocarcinoma, lymphoma (e.g., non-Hodgkin's lymphoma, Hodgkin's lymphoma, cutaneous T-cell lymphoma), leukemia, rectal adenocarcinoma, medulloblastoma, meningioma, neurofibroma (e.g., neurofibrosarcoma), ependymoma, neurilemoma, astrocytoma, melanoma, mesothelioma, myeloma, chronic myeloid leukemia, acute myeloid leukemia, myelodysplastic syndrome, chronic lymphocytic leukemia, epidermoid carcinoma, colon cancer, thymic cancer, blood cancer, head and neck cancer, or oropharyngeal cancer.

[0180] The "infectious diseases" described in the present invention include viral infection, pneumonia with septic shock, peritonitis, bacteremia, sepsis or septicemia; the viral infection is selected from acute viral infection or chronic viral infection; preferably influenza virus, parainfluenza virus, herpes virus (such as HSV-1, EBV), measles virus, vesicular stomatitis virus, hepatitis B virus, hepatitis C virus, human immunodeficiency virus, lymphocytic choriomeningitis virus or human papillomavirus.

[0181] The "autoimmune diseases" described in the present invention include, but are not limited to, GVHD (graft versus host disease), Crohn's disease, atherosclerosis, psoriasis, allergies, asthma, myocarditis, nephritis, hepatitis, systemic lupus erythematosus, rheumatoid arthritis, scleroderma, hyperthyroidism, idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, ulcerative colitis, autoimmune liver disease, diabetes, pain or neurological disorders, etc. BRIEF DESCRIPTION OF THE DRAWINGS

[0182] The embodiments of the present invention are described in detail below with reference to the accompanying drawings, wherein:

[0183] Figure 1 : Technical flow chart of Antigen-Presenting eMigrasome (APM). First, the source cells that produce the migrasomes are genetically engineered to have complete signals for activating T cells (left); second, the antigen-presenting eMigrasomes are prepared, isolated and purified and their in vitro functional tests are performed (middle); finally, the antigen-presenting eMigrasomes are used to perform in vitro and in vivo functional tests to activate immune cells to kill tumors (right).

[0184] Figure 2a :Gene engineering modification of the first signal in the source cells of the antigen self-presenting engineered migrator. (a) Schematic diagram of the first signal of activated T cells modified by the migrator. It contains both MHC class I molecules presenting antigen polypeptides and MHC class II molecules presenting antigen polypeptides.

[0185] Figure 2b : Flow cytometry was used to detect the expression of MHCI / II in wild-type (DC2.4) and DC2.4 cells overexpressing CIITA (DC2.4-CIITA).

[0186] Figure 2c : Schematic diagram of designing the simultaneous expression of MHC class I molecules and corresponding antigenic peptides and MHC class II molecules and corresponding antigenic peptide fusion genes, wherein the upper figure is the expression cassette of the antigenic peptide encoding gene, the lower figure is the expression cassette of the fusion gene of MHC class I molecules and MHC class II molecules, sig is the signal peptide, OVA 257-264 Contains ovalbumin antigenic peptide presented by MHC class I molecules

[0187] OVA 257-264 (LEQLESIINFEKLTEWTS(SEQ ID NO:1)) of (SIINFEKL(SEQ ID NO:3)), OVA 323-339 The invention relates to an antigenic protein (SAESLKISQAVHAAHAEINEAGR (SEQ ID NO: 2)) presented by an MHC class II molecule, wherein the MHC I-Neoantigen is an MHC class I molecule carrying a tumor antigen or a neoantigen, the MHC II-Neoantigen is an MHC class II molecule carrying a tumor antigen or a neoantigen, and LAMP1 represents a lysosomal localization gene.

[0188] Figure 2d : Flow cytometry was used to detect antigen presentation of overexpressed fusion gene.

[0189] Figure 3a : Genetic engineering modification of the second signal in the source cells of the antigen self-presenting engineered migration body, schematic diagram of the second signal.

[0190] Figure 3b :Flow cytometry was used to detect the expression of co-stimulatory molecules CD80 / CD86 / CD137L.

[0191] Figure 3c : The expression of co-stimulatory molecules was detected after DC2.4 cells were treated with IFNγ.

[0192] Figure 4 : Genetically engineer the third signal in the source cells of antigen self-presenting engineered migration bodies.

[0193] in,

[0194] a: Schematic diagram of the third signal.

[0195] b: Schematic diagram of the design of membrane-bound mIL-15-IL-15Rα fusion cytokine.

[0196] mIL-15-IL-15Rα is a fusion membrane protein formed by connecting IL-15 and IL-15Rα with a G4S linker, which can act on IL15Rβγ on the T cell membrane.

[0197] c: Schematic diagram of the design of membrane-bound IL-12 heterodimer fusion cytokine. IL-12 heterodimer is a heterodimer membrane protein formed by connecting the two subunits p35 and p40 of IL12 to Fc6 and Fc9 respectively, and connecting to the transmembrane region of the B7 molecule.

[0198] d: Schematic diagram of the design of membrane-bound IL-12 homodimer fusion protein. mIL12 homodimer is a homodimer membrane protein formed by connecting the two subunits of IL12, p35 and p40, with a G4S linker and connecting them to the transmembrane region of the B7 molecule.

[0199] e: HEK-Blue reporter system detects the function of free IL12.

[0200] f: HEK-Blue reporter system was used to detect the function of membrane-bound IL12.

[0201] Figure 5 : Morphological diagram of antigen self-presenting engineered migration body, in which the three small figures on the right are enlarged views of the boxes in the left figure.

[0202] Figure 6: The antigen self-presenting engineered migratoria membrane contains the migratoria marker molecule Tspan4, wherein the three small pictures on the right are partial enlarged pictures.

[0203] Figure 7 :Western blotting experiments were used to detect proteins enriched on the cell body and antigen self-presenting engineered migration body membrane.

[0204] Figure 8 : Laser confocal microscopy was used to detect MHC class I and MHC class II molecules on the membrane of antigen self-presenting engineered migratoria, as well as the complexes of MHC class I molecules and antigen peptides.

[0205] Fig. 9 :The expression of co-stimulatory molecules in migratory bodies was observed by laser confocal microscopy.

[0206] Fig.10 : Laser confocal microscopy observation of antigen self-presenting engineered migrator MHC class I molecules, MHC class II molecules and antigen presentation.

[0207] Fig.11 : Results of antigen self-presentation engineered migrasomes activating T cells.

[0208] Fig.12 : Effects of antigen self-presenting engineered migsomes containing different signals on the intensity of T cell activation, where WT: negative control migsome, OVA: migsome containing only the first signal, mIL12-mIL15: migsome containing only the third signal membrane-bound cytokine, mIL12-mIL15-OVA: migsome containing all three signals.

[0209] Fig.13 : Effects of antigen self-presenting engineered migsomes containing different signals on the intensity of T cell activation, where MFI represents the mean fluorescence intensity of the activation marker CD25, OVA: migsomes containing only the first signal, mIL12-mIL15: migsomes containing only the third signal, membrane-bound cytokine, and mIL12-mIL15-OVA: migsomes containing all three signals.

[0210] Fig.14 : Effects of antigen self-presenting engineered migrasomes containing different signals on the expression of CD69 and CD25.

[0211] Fig.15 :Effects of different immunization methods on T cell proliferation.

[0212] Fig.16: Organ targeting after further modification of L-selectin and CCR7, where WT: engineered migsome of unmodified L-selectin / CCR7, WT400nm: unmodified L-selectin / CCR7 and extruded to a diameter of 400nm by an extruder, CCR7-SELL: engineered migsome of modified L-selectin / CCR7.

[0213] Fig.17 :Detect the three signals of antigen self-presenting engineered migsomes and verify their functions. Among them, four antigen self-presenting engineered migsomes derived from DC cells were constructed: all groups had the second signal, on this basis, the WT group was not modified; the OVA group modified the first signal; the mIL12-mIL15 group modified the third signal; the mIL12-mIL15-OVA group modified the first and third signals at the same time. The molecules of the three signals were detected by flow cytometry, and the results were consistent with the modification types of different groups.

[0214] Fig.18 : Functional validation of MC38-derived antigen self-presenting engineered misomes.

[0215] a: Tspan4-AcGFP and Tspan4-OVA-AcGFP were expressed in MC38 cells, and the morphology of migratory bodies was observed under laser confocal microscopy, where Tspan4 was used as a migratory body marker;

[0216] b: MC38 cells expressing Tspan4-OVA-AcGFP can detect OVA SIINFEKL submission of

[0217] c: Engineered migratoria produced by MC38 cells expressing Tspan4-OVA-AcGFP expressed MHC class I molecules and presented OVA on their membranes SIINFEKL ;

[0218] d: In vitro activation experiments of OT-I cells showed that the engineered migrasomes produced by MC38 cells expressing Tspan4-OVA-AcGFP can activate OT-I cells to release calcium signals.

[0219] Fig.19 : Anti-tumor function of antigen self-presenting engineered migrator in vivo. (a)(b)(c) C57BL / 6 mice were inoculated with MC38-OVA tumors and immunized with PBS or OVA 10 days later SIINFEKL The engineered migratoria were used to observe the tumor size every 3-5 days. The results showed that the experimental group immunized with migratoria significantly inhibited tumor growth.

[0220] Fig. 20: C57BL / 6 mice were inoculated with MC38 tumors and immunized with PBS or engineered misomes presenting six new antigen peptides of MC38 itself 12 days later. The results showed that the antigen self-presenting engineered misome immunization group and the combination of immune checkpoint inhibitor PD1 antibody could effectively inhibit tumor growth. DETAILED DESCRIPTION

[0221] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only some embodiments of the present invention, not all. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without making creative work are within the scope of protection of the present invention.

[0222] Cells, reagents and equipment used in the examples:

[0223] 1. Cells: Lenti-293X (Takara), DC2.4, MC38, B16-F10, EG7-OVA.

[0224] 2. Flow cytometry antibodies: CD8a-PE(Biolegend#100708), CD3ε-PE(Biolegend#100308), CD25-PE(Invitrogen#12-0251-82), MHCII-PE(Invitrogen#12- 5321-82), CD69-FITC(Biolegend#104505), CD86-APC(Biolegend#104724), CD80–PB(Biolegend#104724), CD137L-PE(ebioscience#12-5901-82), Fc block(BD#553142), CD215-APC(IL-15Rα)(biolegend#153505), PE anti-mouse H-2Kb bound to SIINFEKL (Biolegend #141603), IL-12p35eFluor660 (Invitrogen #50-7352-80), IL-12p40 PE (biolegend #505203).

[0225] 3. Cell culture related reagents: Gibco: RPMI1640, DMEM, DMEM / F12, fetal bovine serum, glutamate (GlutaMax), sodium pyruvate, penicillin-streptomycin, non-essential amino acids, 0.25% trypsin-EDTA digestion solution; DMSO (Amresco); cell transfection reagent PEI and virus-assisted transfection Polybrene (Polysciences); virus concentration reagent PEG8000 (Sigma).

[0226] 4. Animal experiments: C57BL / 6 mice were purchased from the Experimental Animal Center of Tsinghua University and Weitong Lihua. Luciferin substrate (yeasen), disposable sterile syringe (Zhiyu), vernier caliper. Isoflurane anesthetic.

[0227] 5. Instruments, equipment and consumables: biological safety cabinet (Thermo), carbon dioxide incubator (Thermo), shaking incubator (Zhichu Instrument), high-speed centrifuge (Eppendorf), mouse three-dimensional living imager (PE), inverted fluorescence microscope (Olympus), inverted phase contrast microscope (Olympus), flow sorter (BD), flow analyzer (BD), cell culture dish (NEST), cell culture flask (NEST).

[0228] Experimental methods in the embodiments:

[0229] 1. Modification of source cells

[0230] First, design 1) a fusion gene expressing MHC I polypeptide and MHC II polypeptide; 2) a gene expressing a co-stimulatory molecule; and 3) a fusion gene expressing a membrane-bound cytokine.

[0231] Then:

[0232] The above genes are obtained by DNA synthesis or PCR and constructed into lentiviral expression plasmids. The plasmids are packaged by lentivirus; the target plasmid and packaging plasmid are transfected in Lenti-293X cells, and the supernatant is collected after 48 hours and 72 hours, and the virus is concentrated by centrifugation. The source cells of the production migration body are infected with lentivirus. The auxiliary infection reagent polybrene is added during viral infection. The drug-killing gene or fluorescent label or flow cytometry antibody carried by the target plasmid is used to separate and enrich the cells that have been successfully genetically engineered.

[0233] 2. Detection of antigen presentation and membrane receptor expression in antigen self-presenting engineered misomes

[0234] PE anti-mouse H-2Kb-SIINFEK L (Biolegend #141603) antibody was used to detect the presentation of antigen in the migratoria, and the antibodies corresponding to the membrane receptors were used to detect the expression of the corresponding receptors on the migratoria membrane.

[0235] 3. Production, isolation and purification of antigen self-presenting engineered migratoria

[0236] Instruments and consumables: Carbon dioxide incubator, CO2 resistant 2 Horizontal shaker (NEST), high-speed centrifuge (Eppendorf), 6 μm parylene filter (Bai Mai Medical), 50 ml low adsorption tube (Eppendorf), cell culture bottle (NEST), disposable sterile syringe (Zhi Yu).

[0237] Experimental methods:

[0238] I Coating culture flasks and paving cells

[0239] 1) Prepare 4ug / ml human Fibronectin with PBS and coat the bottom of the culture flask. The coating needs to be carried out at 37℃ for more than one hour;

[0240] 2) Follow 5x 10 6 Cells were plated at a density of cell / T175 flask;

[0241] 3) IFNγ was added to the culture medium at a final concentration of 20 ng / ml.

[0242] II Inducing the generation of artificial migratory bodies

[0243] 1) After culturing the cells for about 20 hours, discard the culture medium and wash them once with PBS;

[0244] 2) Add 13.5 ml of K-DPBS containing 0.2 μM latrunculin A to each T175 culture flask and incubate at 37 degrees for 20 minutes;

[0245] 3) Place the culture flask on a horizontal shaker in a cell culture incubator, at 40 rpm, add water every three minutes, for a total of three times. The volume of water added to each T175 culture flask three times is 1.5 ml, 1.7 ml and 1.9 ml respectively;

[0246] 4) Adjust the speed to 60 rpm and shake for 5 minutes.

[0247] III. Isolation and purification of artificial migratory bodies

[0248] 1) Discard the supernatant and wash twice with h-KDPBS (75% KDPBS);

[0249] 2) Add h-KDPBS-BSA, gently blow the bottom of the culture bottle with a pipette, and collect the liquid in a centrifuge tube;

[0250] 3) Centrifuge at 300 x g for 10 min at 4°C and retain the supernatant;

[0251] 4) Centrifuge at 500 x g for 10 min at 4°C and retain the supernatant;

[0252] 5) Filter the supernatant through a 6 μm pore size parylene filter into a 50 ml low adsorption tube;

[0253] 6) Centrifuge at 20,000 x g for 45–60 min at 4°C and discard the supernatant;

[0254] 7) Resuspend the pellet with a small volume of h-KDPBS-BSA, transfer to an EP tube, and add an equal volume of PBS-BSA;

[0255] 8) Centrifuge at 20,000 x g for 20-30 min at 4°C, discard the supernatant and resuspend the precipitate in PBS. Take a small portion of the liquid to measure the protein concentration.

[0256] 9) Add PBS to an appropriate volume according to the measured protein concentration for use in mouse immunization.

[0257] 4. Functional testing of antigen self-presenting engineered migrator

[0258] 1) Ability to activate T cells in vitro

[0259] Purified antigen self-presenting engineered migratoria were co-cultured with T cells, and cells were collected after 12 hours and 24 hours. The collected co-cultured cells were stained by flow cytometry, including T cell activation markers CD69 and CD25, using antibodies at a dilution of 1:200, and stained on ice in the dark for 30 minutes, then washed twice with PBS. The stained cells were analyzed by flow cytometry for the expression of CD69 and CD25.

[0260] 2) In vivo activation and expansion of T cells

[0261] CD8+ T cells isolated from OT-I mice: 2OT-I mice aged 6-9 weeks were euthanized by inhalation and cervical dislocation. The skin was incised using surgical scissors, separated from the body using surgical forceps and tweezers, and the spleen and major lymph nodes (pairs of inguinal, axillary and cervical only) were placed in culture dishes (60×15 mm) with 70 μm pores for tissue grinding and cell release. The culture dishes (each with a mesh cup) were placed in 3-5 mL complete RPMI medium (RPMI 1640, 10% v / v FCS, 100 U / mL penicillin, 50 μg / mL streptomycin) kept on ice. Grind using a syringe plunger or similar sterile tool (no pre-cutting required) and collect the resulting single cell suspension in a 15 mL centrifuge tube. The cell suspension was centrifuged at 300×g for 10 minutes at 4°C. The supernatant was discarded. The cells were washed in 10 mL cold PBS and the red blood cells in the spleen were lysed by resuspending in alcohol ammonium chloride buffer (ACK buffer, commercially available). Incubate on ice for 1.5 min, then wash cells with 10 mL cold PBS by centrifugation (as before). CD8+ T cells were sorted using magnetic beads.

[0262] CSFE staining of OT-I and reinfusion: First, count the number of CD8+ T cells obtained from OT-I mice using an automated cell counter. In a 15 ml tube, dilute 1-5x 10e 7 cells / mL to a volume of 1-5 mL, add 5 μM CFSE, and incubate at 37°C, protected from light, for 7 minutes. Add an equal volume (1:1) of FBS to quench the CFSE stain, protect from light, and incubate at 37°C for an additional 7 minutes. Wash cells twice with 10 mL PBS. Count cells using an automated cell counter. Adjust cell concentration to 3-5 x 10 7 cells / mL PBS for injection of 3-5x 10 cells / mL in 100 μL tail vein injection suspension 6 cells / mouse.

[0263] Immunoengineered migrasomes: One day after the reinfusion of OT-I cells, mice were immunized with PBS via tail vein as a control, and the experimental group was immunized with migrasomes presenting the OVA epitope SIINFEKL (30ug / mouse) via tail vein.

[0264] Immune antigen peptide and adjuvant: One day after the reinfusion of OT-I cells, the mice were immunized with PBS in the tail vein as a control group, and the experimental group was immunized with peptide SIINFEKL + Freund's adjuvant CFA (100ug / mouse) in the tail vein.

[0265] Lymphocyte separation, staining and flow cytometry detection of OT-I proliferation: Lymphocytes and spleen cells were separated. 2Euthanize the inoculated mice. Remove the lymph nodes and spleen and place them in a culture dish with 100 μm pores for tissue grinding and cell release. After centrifugation, pour off the supernatant and resuspend the cell pellet in the same volume of residual PBS (approximately 100 μl). Stain for flow cytometry analysis: In a 15 ml centrifuge tube, add the mixture of staining antibodies to make 100 μl for each sample. Mix the cells and the mixture in a 1:1 ratio and incubate at 4°C for 30 minutes. After staining, add PBS and wash the cells twice by centrifugation. Suspend the stained cells in 0.5-1 ml of PBS for collection and transfer the suspension to a flow cytometer tube. Always keep samples on ice and protect from light.

[0266] 3) Anti-tumor ability in vivo

[0267] Healthy C57B / 6 mice of 6-8 weeks were inoculated with tumors. About 7-12 days later, engineered migratoria (20-50ug / mouse) and PBS control group were intravenously immunized. Tumor size was measured with a vernier caliper or tumor growth was detected using a mouse in vivo imaging device every 3-5 days.

[0268] Example 1: Genetic engineering of source cells of antigen self-presenting engineered migrasomes

[0269] This example uses DC2.4 cells as an example, and genetically engineered them, which are then used as source cells for antigen self-presenting engineered migrator. Among them, the genetically engineered dendritic cells have three complete signals for activating T cells: 1) MHC-presented polypeptides as the first signal to achieve antigen-specific activation of T cells; 2) co-stimulatory molecules such as CD80 / CD86 / CD37L as the second signal; 3) secreted cytokines as the third signal.

[0270] The antigen self-presenting engineered migrator obtained by separation and purification has three signals to activate T cells: 1) polypeptides that can present tumor antigens autonomously; 2) various co-stimulatory molecules expressed on the membrane; 3) cytokines in membrane-bound form. In vivo and in vitro experiments have shown that antigen self-presenting engineered migrator has the ability to activate T cells and kill tumors (see the technical process for details). Figure 1 ). The specific steps are as follows:

[0271] 1. Functional modification of the first signal (e.g. Figure 2a )

[0272] On the source cell DC2.4, MHC class I molecules are highly expressed, but MHC class II molecules are lowly expressed; overexpression of CIITA can significantly increase the expression of MHC class II molecules, thereby facilitating the activation of CD4 T cells by presenting antigenic peptides of MHC class II molecules ( Figure 2bIn addition, a fusion gene capable of simultaneously expressing MHC class I antigen polypeptide and MHC class II antigen polypeptide was designed ( Figure 2c , see SEQ ID NO: 5). This design can be extended to simultaneously express MHC class I antigen polypeptides and MHC class II new antigen polypeptides. At the cellular level, flow cytometry analysis can be used to detect the complex of MHC class I molecules and antigen polypeptides on the cell membrane ( Figure 2d ).

[0273] MAAPGARRPLLLLLAGLAHGASALFEDLVDSAESLKISQAVHAAHAEI NEAGREVVGSALEQLESIINFEKLTEWTSCTLNNMLIPIAVGGALAGLVLIVLI AYLIGRKRSHAGYQTI(SEQ ID NO: 5)

[0274] 2. Functional modification of the second signal

[0275] The source cells of the antigen self-presenting engineered migrator are further modified with the function of the second signal (co-stimulatory molecule) Figure 3a Flow cytometry showed that the co-stimulatory molecules CD80 / CD86 / CD37L were expressed in DC2.4 cells ( Figure 3b Further stimulation of DC2.4 cells with the cytokine IFNγ can slightly upregulate the expression of co-stimulatory molecules ( Figure 3c ).

[0276] 3. Functional modification of the third signal

[0277] Functional modification of the third signal (cytokine) in the source cells of the antigen self-presenting engineered migrator Figure 4 a). The third signal for activating T cells is free cytokines secreted by antigen presenting cells, such as IL2, IL15, IL12, etc. Membrane-bound cytokines m-IL12 and mIL-15 were designed, wherein the membrane-bound cytokine mIL-15 is shown in SEQ ID NO: 6, and is stably expressed on the DC2.4 cell membrane ( Figure 4 b, 4c, 4d). The functions of free IL12 and membrane-bound IL12 were compared using the HEK-Blue reporter system, and the results showed that 5000 DC2.4 cells expressing membrane-bound m-IL12 were sufficient to achieve the effect of 100 mg / mL IL12 ( Figure 4 e, 4f).

[0278] MASPQLRGYGVQAIPVLLLLLLLLLPLRVTPNWIDVRYDLEKIESLIQSIHIDTTLYTDSDFHPSCKVTAMNCFLLELQVILHEYSNMTLNETVRNVLYLANSTLSSNKNVAESGCKECEELEEKTFTEFLQSFIRIVQMFINTSSGGGSGGGGSGGGGSGGGGSGGGSLQGTTCPPPVSIEHADIRVKNYSVNSRERYVCN SGFKRKAGTSTLIECVINKNTNVAHWTTPSLKCIRDPSLAHYSPVPTVVTPKVTSQPESPSPSAKEPEAFSPKSDTAMTTETAIMPGSRLTPSQTTSAGTTGTGSHKSSRAPSLAATMTLEPTASTSLRITEISPHSSKMTKVAISTSVLLVGAGVVMAFLAWYIKSRQPSQPCRVEVETMETVPMTVRASSKEDEDTGA(SEQ ID NO:6)

[0279] Example 2: Characterization and detection of antigen self-presenting engineered migrasomes

[0280] Based on the genetically engineered source cells of Example 1, antigen self-presenting engineered migrasomes were prepared.

[0281] 1. Characterization of the morphology and marker molecules of antigen self-presenting engineered misomes:

[0282] Antigen self-presentation engineered migratoria are in the form of extracellular vesicles ( Figure 5 ), with a diameter of about 10 μm, the antigen self-presenting engineered migration body membrane contains the migration body marker molecule Tspan4 (green fluorescent protein marker), see Figure 6 In addition, immunoblotting experiments revealed that compared with cell bodies, antigen self-presenting engineered migratoria membranes were enriched with integrin α5 and other cell membrane components (see Figure 7 ).

[0283] 2. Characterization of the first signal of T cell activation on the membrane of antigen self-presenting engineered migratoria:

[0284] Laser confocal microscopy can detect MHC class I and MHC class II molecules on the membrane of antigen self-presenting engineered migratoria (see Figure 8 ). At the same time, the MHC class I molecules and antigen-peptide complexes on the antigen self-presenting engineered migration body membrane can be detected.

[0285] 3. Characterization of the second signal of T cell activation on the membrane of antigen self-presenting engineered migratoria:

[0286] Laser confocal microscopy can detect CD80, CD86, CD137L and other co-stimulatory molecules on the membrane of engineered migratoria (see Fig. 9 ).

[0287] 4. Characterization of the third signal of T cell activation on the membrane of antigen self-presenting engineered migratory bodies:

[0288] Laser confocal microscopy was used to detect membrane-bound cytokines IL-12, IL-15-IL15Rα ( Fig.10 ).

[0289] Example 3: Antigen self-presenting engineered migrasomes can activate and expand immune cells in vitro

[0290] 1. Antigen self-presenting engineered migratoria (prepared in Example 1) can activate T cells and cause them to undergo cell morphological changes

[0291] In vitro, the traditional CD3 / CD28 antibody or antigen self-presenting migrator was used to co-culture with naive T cells. The results showed that the T cells activated by CD3 / CD28 antibody became larger and more numerous; the naive T cells treated with antigen self-presenting engineered migrator for 24 hours were also activated, the cell morphology became larger, and the cells were in the form of cell clusters, indicating that the T cells treated with antigen self-presenting engineered migrator were fully activated and proliferated ( Fig.11 ).

[0292] 2. Antigen self-presenting engineered migsomes can activate T cells to express the activation marker CD25. Antigen self-presenting migsomes prepared were co-cultured with naive OT-I T cells in vitro, and the T cell activation marker CD25 was detected. This shows that antigen self-presenting engineered migsomes containing complete T cell activation signals can also better activate naive T cells ( Figure 12-13 ). Fig.14 It is shown that compared with antigen self-presenting engineered migration bodies with only the first signal, antigen self-presenting engineered migration bodies containing the first signal (MHC and antigen polypeptide) and the second signal (co-stimulatory molecules) can more strongly upregulate the expression of CD69 and CD25, thereby better activating T cells.

[0293] Example 4: Antigen self-presenting engineered migrator can activate and expand immune cells in vivo

[0294] Intravenous immune antigen self-presenting engineered migrator (prepared in Example 1) can activate the proliferation of naive T cells in vivo. The proliferation effect of immune antigen self-presenting engineered migrator alone can achieve the proliferation effect of immune polypeptide plus adjuvant (see Fig.15 ).

[0295] Example 5: Antigen self-presenting engineered migrasomes can activate immune cells and kill tumor cells in vitro

[0296] In vitro, naive T cells were co-cultured with conventional CD3 / CD28 antibodies or antigen self-presenting engineered migratoria, or left untreated. T cells under different treatment conditions were co-cultured with antigen-expressing tumor cells MC38, B16-F10, EG7-OVA, etc. in vitro to detect tumor cell killing and T cell effector functions such as secretion of cytokines IFN-γ and TNF-α.

[0297] Example 6: Antigen self-presenting engineered migsomes can be further modified with anti-phagocytic proteins such as CD47 to extend the half-life of migsomes in vivo

[0298] The source cells of the antigen self-presenting engineered migration bodies were further modified with anti-phagocytic proteins such as CD47, and the half-life of the antigen self-presenting engineered migration bodies in vivo was detected.

[0299] Example 7: Antigen self-presenting engineered misomes Further modification of receptors such as L-selectin (SELL), CCR7, etc. can enhance the targeting of engineered misomes to immune organs in vivo.

[0300] The source cells of antigen self-presenting engineered migsomes were further modified with receptors such as L-selectin and CCR7, and engineered migsomes labeled with fluorescent dyes were intravenously infused to detect the organ targeting of antigen self-presenting engineered migsomes in vivo, especially spleen and lymph node targeting (see the results). Fig.16 ).

[0301] Example 8: Antigen self-presenting engineered migrator can kill tumors in vivo

[0302] The antigen self-presenting engineered migrator prepared in Example 1 was functionally verified. First, experimental groups with different signals were constructed in DC2.4 cells ( Fig.17 In another cell type, MC38, the migrator modified with the first and second signals can directly present antigens ( Fig.18 a, 18b), co-stimulatory molecules expressed on the membrane ( Fig.18 c) and can well activate antigen-specific somatic cells in vitro and in vivo ( Fig.18 d). Further in vivo anti-tumor experiments were performed using engineered misomes isolated from modified MC38. The results showed that antigen self-presenting engineered misomes showed good anti-tumor ability in OVA antigen tumor model and neoantigen tumor model ( Fig.19 ).

[0303] Example 9: Antigen self-presenting engineered migratoria can inhibit tumor growth in vivo in combination with immune checkpoint inhibitor PD-1 antibody

[0304] Results Fig. 20 As shown, antigen self-presenting engineered migratoria can inhibit tumor growth in vivo in combination with the immune checkpoint inhibitor PD-1 antibody.

[0305] The preferred embodiments of the present invention are described in detail above. However, the present invention is not limited to the specific details in the above embodiments. Within the technical concept of the present invention, a variety of simple modifications can be made to the technical solution of the present invention, and these simple modifications all belong to the protection scope of the present invention.

[0306] It should also be noted that the various specific technical features described in the above specific embodiments can be combined in any suitable manner without contradiction. In order to avoid unnecessary repetition, the present invention will not further describe various possible combinations.

Claims

1. An antigen self-presenting engineered migrator, characterized in that: The antigen self-presenting engineered migrator contains a major histocompatibility complex (MHC) or a variant thereof that presents an antigen polypeptide, and the antigen self-presenting engineered migrator expresses co-stimulatory molecules and cytokines; Preferably, the antigen self-presenting engineered migrator is an extracellular vesicle.

2. The antigen self-presenting engineered migrator according to claim 1, characterized in that: The MHC includes MHC class I molecules and / or MHC class II molecules.

3. The antigen self-presenting engineered migrator according to claim 1, characterized in that: The co-stimulatory molecules are expressed on the membrane of the antigen self-presenting engineered migrator.

4. The antigen self-presenting engineered migrator according to claim 3, characterized in that: The co-stimulatory molecules are selected from one or more of CD28, CD80, CD86, CD40, ICAM1, ICAM2, LFA-3, HSA, VCAM-1, 4-1BB, 4-1BBL, CTLA-4, PD-1, ICOS or CD37L.

5. The antigen self-presenting engineered migrator according to claim 1, characterized in that: The cytokine is selected from one or a combination of two or more of the interleukin, colony stimulating factor, interferon, tumor necrosis factor, transforming growth factor-β, growth factor or chemokine family.

6. The antigen self-presenting engineered migrator according to any one of claims 1 to 5, characterized in that: The cytokine is a membrane-bound cytokine, preferably one or a combination of two or more of membrane-bound IL12, membrane-bound IL15, membrane-bound IL10, membrane-bound IL18, membrane-bound IL2, membrane-bound IL7 or membrane-bound IL21.

7. The antigen self-presenting engineered migrator according to any one of claims 1 to 6, characterized in that: The antigen is selected from tumor antigens, tumor neoantigens or tumor cell antigens; Preferably, the antigen self-presenting engineered migrator contains an antigen polypeptide; Further preferably, the antigen or antigen polypeptide is present inside and / or on the surface of the antigen self-presenting engineered migrator.

8. The antigen self-presenting engineered migrator according to claim 7, characterized in that: The tumor can be a hematological tumor or a solid tumor; preferably, the tumor is selected from prostate cancer, breast cancer, liver cancer, glioma, intestinal cancer, cervical cancer, non-small cell lung cancer, lung cancer, pancreatic cancer, gastric cancer, bladder cancer, skin cancer, rhabdomyosarcoma, tongue squamous cell carcinoma, nasopharyngeal carcinoma, ovarian cancer, placental choriocarcinoma, lymphoma, leukemia, rectal adenocarcinoma, medulloblastoma, meningioma, neurofibroma, ependymoma, schwannoma, astrocytoma, melanoma, mesothelioma, myeloma, chronic myeloid leukemia, acute myeloid leukemia, myelodysplastic syndrome, chronic lymphocytic leukemia, epidermoid carcinoma, colon cancer, thymic carcinoma, blood cancer, head and neck cancer or oropharyngeal cancer.

9. The antigen self-presenting engineered migrator according to any one of claims 1 to 8, characterized in that: The antigen self-presenting engineered migrator can activate and / or expand immune cells.

10. The antigen self-presenting engineered migrator according to any one of claims 1 to 9, characterized in that: The antigen self-presenting engineered migrator presents antigen polypeptides to immune cells, and cooperates with co-stimulatory molecules and cytokines to activate and / or amplify immune cells.

11. The antigen self-presenting engineered migrator according to any one of claims 1 to 10, characterized in that: The antigen self-presenting engineered migrator is separated from source cells or generated from tissues; Preferably, the source cells may be ex vivo cells; Preferably, the source cells are living cells; Preferably, the source cells are selected from tumor cells, immune cells, HEK293 cells, fibroblasts, amniotic cells, amniotic epithelial cells, placenta-derived cells, umbilical cord blood cells, endothelial cells, epithelial cells or mesenchymal stem cells.

12. The antigen self-presenting engineered migrator according to claim 11, characterized in that: The immune cells are selected from lymphocytes, dendritic cells, macrophages, granulocytes or mast cells.

13. The antigen self-presenting engineered migrator according to claim 11 or 12, characterized in that: The source cells contain antigen polypeptides, MHC or its variants expressing and presenting the antigen polypeptides, co-stimulatory molecules and cytokines; Preferably, the cytokine is a membrane-bound cytokine and is expressed on the membrane; Preferably, the source cells can activate and / or expand immune cells.

14. A genetically modified cell that produces an antigen self-presenting engineered migrator, characterized in that: The genetically modified cells contain antigenic polypeptides, MHC or its variants expressing and presenting the antigenic polypeptides, co-stimulatory molecules and cytokines; Preferably, the cytokine is a membrane-bound cytokine and is expressed on the membrane; Preferably, the source cells can activate and / or expand immune cells.

15. A method for preparing a genetically modified cell according to claim 14, characterized in that: The preparation method comprises introducing a nucleic acid sequence encoding a membrane-bound cytokine into a genetically modified cell.

16. The preparation method according to claim 15, characterized in that: The preparation method comprises introducing nucleic acid encoding antigen polypeptide and / or co-stimulatory molecule into genetically modified cells.

17. The preparation method according to claim 15 or 16, characterized in that: The preparation method comprises stimulating genetically modified cells with cytokines to increase the expression amount of costimulatory molecules.

18. The preparation method according to any one of claims 15 to 17, characterized in that: The genetically modified cells are selected from tumor cells, immune cells, HEK293 cells, fibroblasts, amniotic cells, amniotic epithelial cells, placenta-derived cells, umbilical cord blood cells, endothelial cells, epithelial cells or mesenchymal stem cells.

19. The preparation method according to claim 18, characterized in that: The immune cells are selected from lymphocytes, dendritic cells, macrophages, granulocytes or mast cells.

20. A method for preparing an antigen self-presenting engineered migrator, characterized in that: The antigen self-presenting engineered migrator is separated from the genetically modified cell according to claim 14 or the genetically modified cell obtained by the preparation method according to any one of claims 15-19.

21. Use of the antigen self-presenting engineered migration body described in any one of claims 1 to 13, the genetically modified cell described in claim 14, the genetically modified cell obtained by the preparation method described in any one of claims 15 to 19, or the antigen self-presenting engineered migration body obtained by the preparation method described in claim 20 in activating and / or amplifying immune cells or preparing products for treating or preventing diseases.

22. An antigen self-presenting engineered migration body as described in any one of claims 1-13, the genetically modified cell as described in claim 14, the genetically modified cell obtained by the preparation method as described in any one of claims 15-19, or the antigen self-presenting engineered migration body obtained by the preparation method as described in claim 20, used in combination with chemotherapeutic drugs and / or immunomodulators in activating and / or amplifying immune cells or preparing products for treating or preventing diseases.

23. The use according to claim 22, characterized in that The chemotherapeutic drug is selected from alkylating agents, antimetabolites, plant anticancer drugs, hormones, antibiotics or immune preparations; Preferably, the chemotherapy drug is selected from paclitaxel, doxorubicin, gemcitabine or cisplatin.

24. The use according to claim 22, characterized in that The immunomodulators include immune checkpoint inhibitors, such as one or more of PD-1 antibodies, PD-L1 antibodies, CTLA-4 antibodies, Tim-3 antibodies, LAG-3 antibodies or TIGHT antibodies.

25. The use according to any one of claims 21 to 24, characterized in that: The disease is an infectious disease, an autoimmune disease or a tumor.

26. The use according to claim 25, characterized in that The infectious disease is selected from bacterial infection, viral infection or fungal infection.

27. The use according to claim 25, characterized in that The tumor can be a hematological tumor or a solid tumor; preferably, the tumor is selected from prostate cancer, breast cancer, liver cancer, glioma, intestinal cancer, cervical cancer, non-small cell lung cancer, lung cancer, pancreatic cancer, gastric cancer, bladder cancer, skin cancer, rhabdomyosarcoma, tongue squamous cell carcinoma, nasopharyngeal carcinoma, ovarian cancer, placental choriocarcinoma, lymphoma, leukemia, rectal adenocarcinoma, medulloblastoma, meningioma, neurofibroma, ependymoma, schwannoma, astrocytoma, melanoma, mesothelioma, myeloma, chronic myeloid leukemia, acute myeloid leukemia, myelodysplastic syndrome, chronic lymphocytic leukemia, epidermoid carcinoma, colon cancer, thymic carcinoma, blood cancer, head and neck cancer or oropharyngeal cancer.

28. A drug or a pharmaceutical composition, characterized in thatThe drug or pharmaceutical composition comprises the antigen self-presenting engineered migration body described in any one of claims 1-13, the genetically modified cell described in claim 14, the genetically modified cell obtained by the preparation method described in any one of claims 15-19, or the antigen self-presenting engineered migration body obtained by the preparation method described in claim 20, and pharmaceutically acceptable excipients.

29. The drug or pharmaceutical composition according to claim 28, characterized in that The pharmaceutical composition also includes components used in combination with antigen self-presenting engineered migratory bodies and genetically modified cells; preferably, the components are selected from chemotherapeutic drugs, RNA drugs, antisense oligonucleotides, antibodies or immunomodulators.

30. The drug or pharmaceutical composition according to claim 29, characterized in that The chemotherapeutic drug is selected from alkylating agents, antimetabolites, plant anticancer drugs, hormones, antibiotics or immune preparations; Preferably, the chemotherapy drug is selected from paclitaxel, doxorubicin, gemcitabine or cisplatin.

31. The drug or pharmaceutical composition according to claim 29 or 30, characterized in that The immunomodulator includes one or more of the immune checkpoint inhibitors PD-1 antibody, PD-L1 antibody, CTLA-4 antibody, Tim-3 antibody, LAG-3 antibody or TIGHT antibody.

32. A method for activating and / or amplifying immune cells, characterized in that: The method comprises contacting the antigen self-presenting engineered migration body described in any one of claims 1-13, the genetically modified cell described in claim 14, the genetically modified cell obtained by the preparation method described in any one of claims 15-19, the antigen self-presenting engineered migration body obtained by the preparation method described in claim 20, or the drug or pharmaceutical composition described in any one of claims 28-31 with immune cells.

Citation Information

Patent Citations

  • Preparation method of targeted extracellular vesicles for treating drug-resistant tumors

    CN111544391A

  • Extracellular vesicles with improved half-life

    CN115843241A

  • Exosome based treatment of cancer

    WO2011000551A1